Now IRT gets significant update and a portion of new data
[Moscow – 22.07.2021] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, launches Immune Response Template (IRT) version 3.5.0.
Elena Vasileva, student of Lomonosov Moscow State University (MSU) has developed her diploma thesis in InSysBio and successfully passed its defense. Her diploma thesis entitled “Optimization of anti-CD47 therapeutic agent dosage using PK/PD modeling” was supervised by Oleg Demin Jr, Head of Oncology and Immuno-Oncology at InSysBio.
[Moscow – 19.05.2021] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, launches the new version (0.3.0) of its SbmlViewer open project. Generally, SbmlViewer is a tool for fast and easy reading and transformation of biological models written in SBML format.
InSysBio presents the major updates of Heta compiler. Heta compiler is a software tool for development of QSP modeling platforms. In fact, its core option is the compilation of Heta-based platforms. Its functionality has been significantly elaborated and now Heta compiler has become even more useful and functional.
IRT gets new data and recalculated parameters
[Moscow – 30.03.2021] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, launches Immune Response Template (IRT) version 3.4.0. IRT represents a Quantitative Systems Pharmacology (QSP) platform of immune system simultaneously being a tool for development of models related to immune system. IRT is based on two main components.
[Moscow – 15.02.2021] Oleg Demin Jr, Head of Oncology and Immuno-Oncology at InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, has talked to startup.info, a global innovation ecosystem magazine. The interview in frames of the series "INNOVATORS VS COVID-19" covers the application of system-pharmacology modeling to different stages of drug research and development and InSysBio's current development in the context of the pandemic.
We use cookies (and other similar technologies) to collect data to improve your experience on our site.
By using our website, you agree to data collection as described in our website’s data collection policy.